Using imaging techniques like CT and PET scans to detect and characterize cancerous tumors and metastases.Medical imaging in oncology uses techniques like computed tomography (CT) and positron emission tomography (PET) to detect, characterize, and monitor cancerous tumors and metastases. These methods allow clinicians to visualize the location, size, and metabolic activity of tumors without invasive procedures. The field has evolved from simple anatomical imaging to functional and molecular imaging, enabling earlier detection and more precise treatment planning.
The concept of using imaging for cancer detection dates to the early 20th century with X-rays, but modern CT emerged in the 1970s (Hounsfield and Cormack), and PET was developed in the 1950s–1970s. The fusion of PET and CT became standard in the 2000s.
CT scans use X-rays to create detailed cross-sectional images of the body, revealing tumor size and shape. PET scans inject a radioactive tracer, often fluorodeoxyglucose (FDG), which accumulates in metabolically active cells like cancer cells; the emitted positrons are detected to map metabolic activity. Combining both (PET/CT) overlays functional and anatomical data, helping distinguish benign from malignant lesions and track treatment response.
Used routinely in oncology for staging, treatment planning, and assessing response to therapy, such as in lung, breast, and prostate cancers.
PET scans can detect tumors as small as a few millimeters, but the resolution is limited by the physics of positron annihilation, not just the scanner.

















